Piperazine → HCID 59511338、化合物
反応式
Br[C:2]1[CH:7]=[CH:6][C:5]([C:8]2[CH:9]=[N:10][C:11]([NH2:14])=[N:12][CH:13]=2)=[CH:4][CH:3]=1.C(=O)([O-])[O-].[Cs+].[Cs+].[NH:21]1[CH2:26][CH2:25][NH:24][CH2:23][CH2:22]1.C1(C2C=CC=CC=2)C=CC=CC=1>O1CCOCC1.C(Cl)Cl.O.C([O-])(=O)C.[Pd+2].C([O-])(=O)C>[N:21]1([C:2]2[CH:7]=[CH:6][C:5]([C:8]3[CH:9]=[N:10][C:11]([NH2:14])=[N:12][CH:13]=3)=[CH:4][CH:3]=2)[CH2:26][CH2:25][NH:24][CH2:23][CH2:22]1参加物
9
実験手順
A mixture of 5-(4-bromo-phenyl)-pyrimidin-2-ylamine (100 mg, 0.401 mmol), palladium acetate (20 mg, 0.089 mmol), cesium carbonate (200 mg, 0.62 mmol), piperazine (100 mg, 1.16 mmol) and 2-di-t-butylphosphino)-biphenyl (50 mg, 0.167 mmol) was stirred in dioxane:water (10 ml, v/v 5:1) at reflux temperature for 4 hours. The reaction was cooled, diluted with MeCl2 (100 ml) and H2O (50 ml). The organic layer was separated, dried (MgSO4), filtered and solvent evaporated. The residue was purified by chromatography eluting with 100% EtOAc then with 10% v/v MeOH/EtOAc/NH4OH yielding product 82 as a white solid. (70 mg. 68%) ESMS (MH, 256).
後処理
- temperatureThe reaction was cooled
- customThe organic layer was separated
- dry with materialdried (MgSO4)
- filtrationfiltered
- customsolvent evaporated
- customThe residue was purified by chromatography
- washeluting with 100% EtOAc
出典と根拠
- ORDレコード
- ord-c15044741d9b418cbe8cfeb46683003a
- 出典データセット
- uspto-grants-2013_10
- 特許番号
- US08546404B2
反応ノート
読み込み中…